Deal-Making in the Current Environment: A Fireside Chat with Alban de La Sablière, Head of Partnering, Sanofi

Since November 2019, Alban de La Sablière has been SVP Global Head of Partnering, that includes the Sanofi Ventures Fund, Business Development & Licensing and Alliance Management. Previously SVP Head of Business Development & Licensing, over the last two years, he has overseen repositioning of the Business Development activities in line with Sanofi strategy, including partnership deals with Biond Biologics, C4X, Eureka Therapeutics, Abl-Bio, Seagen, Blackstone and IGM Biosciences, and multiple ventures investments including Muna Therapeutics, Rome Therapeutics, Recode Therapeutics, Normunity and Omass Therapeutics. Alban joined Sanofi in January 2016 as SVP, Head of Mergers & Acquisition where he led the Bioverativ, Ablynx and Protein Sciences acquisitions, and portfolio-reshaping divestments including the sale of Zentiva. Prior to joining Sanofi, Alban worked for Morgan Stanley, where he worked with Sanofi on deals, including the merger of Sanofi & Aventis and the Genzyme acquisition.